Hemp-Derived THC Regulatory Landscape Remains Unsettled

The 2018 Farm Bill opened a legal pathway for hemp cultivation and commerce, defining hemp as cannabis containing no more than 0.3 percent delta-9 tetrahydrocannabinol on a dry weight basis. That narrow botanical distinction, intended to separate industrial hemp from marijuana, has created an expanding market for intoxicating products derived from hemp that exist in a regulatory gray zone, prompting federal agencies, state legislatures, and Congress to grapple with a patchwork of conflicting rules.

The Gap Between Federal Definition and Market Reality

The Farm Bill removed hemp from Schedule I of the Controlled Substances Act, but it did not anticipate the rapid emergence of chemically converted cannabinoids such as delta-8 THC, delta-10 THC, and hexahydrocannabinol (HHC). These compounds are synthesized from cannabidiol (CBD) extracted from legal hemp, then converted through chemical processes into intoxicating substances that technically meet the federal definition of hemp-derived products. The Drug Enforcement Administration issued an interim final rule in 2020 stating that synthetically derived tetrahydrocannabinols remain Schedule I controlled substances, but enforcement has been inconsistent and the legal interpretation remains contested.

The Food and Drug Administration has asserted regulatory authority over ingestible hemp-derived products, particularly those containing CBD or other cannabinoids, under the Federal Food, Drug, and Cosmetic Act. However, the agency has yet to establish a comprehensive regulatory framework for these products. FDA officials have testified before Congress that the agency lacks sufficient resources and clear statutory authority to oversee the burgeoning market, leaving products on shelves without pre-market review, standardized labeling, or enforceable potency limits.

State Responses and the Fragmentation of Regulation

In the absence of federal clarity, states have taken divergent approaches. More than a dozen states have enacted laws explicitly prohibiting or restricting delta-8 THC and other hemp-derived intoxicants, while others have moved to regulate them similarly to adult-use cannabis programs, imposing testing requirements, potency caps, and age restrictions. Some states, including those without legalized marijuana, have become de facto hubs for hemp-derived THC commerce, with products widely available in gas stations, vape shops, and online retailers.

State regulators have voiced concerns about product safety, particularly regarding the lack of testing standards and the potential for contamination with residual solvents, heavy metals, or inaccurate labeling of cannabinoid content. Public health officials have reported increases in adverse events and emergency room visits related to high-potency hemp-derived edibles, particularly among adolescents who may perceive these products as less risky than marijuana.

Congressional Debate and the Path Forward

Legislative efforts to address the hemp-derived intoxicant market have stalled amid broader disagreements over cannabis policy. Proposed bills in the House and Senate have sought to amend the Farm Bill's definition of hemp to exclude intoxicating cannabinoids or to grant the FDA explicit authority to regulate these products as drugs. Agricultural committees have heard testimony from hemp farmers concerned that regulatory crackdowns could harm legitimate fiber and grain operations, while law enforcement groups and pediatric health organizations have called for stricter controls.

The upcoming reauthorization of the Farm Bill presents a legislative opportunity to clarify the definition of hemp and establish federal guardrails, but consensus remains elusive. Industry stakeholders have advocated for a tiered regulatory approach that distinguishes between non-intoxicating CBD products and intoxicating cannabinoids, while some lawmakers have argued for outright prohibition of chemically converted compounds.

Until Congress acts or the FDA asserts clearer regulatory authority, the market for hemp-derived THC products will likely continue to grow under a fragmented system that leaves consumers, businesses, and regulators navigating uncertain legal terrain.